• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Immuno cell therapy-clinical application to ovarian cancer patients

Research Project

Project/Area Number 14571555
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Obstetrics and gynecology
Research InstitutionMie University

Principal Investigator

OKUGAWA Toshiharu  Mie University, School of Medicine, Department of Obstetrics and Gynecology, Assistant Professor, 医学部附属病院, 講師 (90262998)

Co-Investigator(Kenkyū-buntansha) TABATA Tsutomu  Mie University, School of Medicine, Department of Obstetrics and Gynecology, Associate Professor, 医学部, 助教授 (40252358)
NISHIURA Keisuke  Mie University, School of Medicine, Department of Obstetrics and Gynecology, Assistant Professor, 医学部, 助手 (80345975)
豊田 長康  三重大学, 医学部, 教授 (40126983)
Project Period (FY) 2002 – 2004
Project Status Completed (Fiscal Year 2004)
Budget Amount *help
¥2,700,000 (Direct Cost: ¥2,700,000)
Fiscal Year 2004: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 2003: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 2002: ¥1,200,000 (Direct Cost: ¥1,200,000)
Keywordscancer vaccine / ovarian cancer / HER2 / 腫瘍免疫 / 癌抗原ペプチド / 抗原ペプチド
Research Abstract

I got start permission of an examination after I made acquisition (I pass authorization about Safety and Quality of HER2 peptide and finish approval in FDA), a vaccine therapy protocol by HER2 peptide from Australian LICR and submitted a clinical test application to Mie University Institutional Reviewer Board, and having discussed peptide for clinical test enough on applying HER2 peptide to Homo sapiens. Patient eligibility criteria was : 1) cancer notice was considered and being a cancer patient of HER2 positive, 2) HLA-A2402 maintainers, 3) resistant to standard therapy such as operations/chemotherapy/radiotherapy, and 4) enough informed consent decided to be provided. For the patient who satisfied eligibility criteria, I used a dose-escalation study of peptide and performed safety evaluation to observe a harmful phenomenon. HER2 positive ovarian cancer/breast cancer/lung cancer patient 10 in total were registered, but, in cancer vaccine clinical test, the harmful phenomenon was not accepted. Delay-related hypersensitivity reaction (DTH) was observed during an examination in one example, and DTH made it positive during the continuation dosage after the end in one example again. In addition, I understood that I could almost guide immune response for cancer in all examples in the cancer patient body by injecting HER2 peptide. Furthermore, I injected vaccine immunity more than six times repeatedly, and it understood that, in addition, it used GM-CSF together that immune reaction was strengthened. The tumor reduction effect had neither example by observation, but the cancer vaccine which I used HER2 peptide for was safe clinically without accepting a harmful phenomenon.

Report

(4 results)
  • 2004 Annual Research Report   Final Research Report Summary
  • 2003 Annual Research Report
  • 2002 Annual Research Report
  • Research Products

    (9 results)

All 2006 2005 2004 2002 2000 Other

All Journal Article (8 results) Publications (1 results)

  • [Journal Article] 悪性腫傷に対する免疫療法の現状2006

    • Author(s)
      奥川利治
    • Journal Title

      産婦人科の世界 58(5)

      Pages: 53-62

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] 卵巣癌の細胞免疫療法2005

    • Author(s)
      奥川利治
    • Journal Title

      産婦人科治療 90(6)

      Pages: 1028-1034

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Case of mature cystic teratoma of the greater omentum misdiagnosed as ovarian cyst.2005

    • Author(s)
      Yoshida A, Okugawa T
    • Journal Title

      The Journal of Obstetrics and Gynecology Research 31(5)

      Pages: 399-403

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] A pilot study of neoadjuvant chemotherapy with mitomycin C, etoposede, cisplatin, etoposide, cisplatin, and epirubicin for adenocarcinoma of the cervix.2004

    • Author(s)
      Tabata T, Okugawa T
    • Journal Title

      International Journal of Clinical Oncology 9

      Pages: 59-63

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] A pilot study of neoadjuvant chemotherapy with mitomycin C, etoposide, cisplatin, and epirubicin for adenocarcinoma of the cervix.2004

    • Author(s)
      Tabata T, Okugawa T
    • Journal Title

      International Journal of Clinical Oncology 9

      Pages: 59-63

    • NAID

      80016574111

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex : implications for a polyvalent immuno-cell therapy.2002

    • Author(s)
      Ikuta Y, Okugawa T
    • Journal Title

      Blood 99(10)

      Pages: 3717-3724

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA- A24-restricted cytotoxic T lymphocytes In ovarian cancer patients and healthy individuals.2000

    • Author(s)
      Okugawa T
    • Journal Title

      European Journal of Immunology 30(11)

      Pages: 3338-3346

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA- A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals.2000

    • Author(s)
      Okugawa T
    • Journal Title

      European Journal of Immunology 30(11)

      Pages: 3338-3346

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Publications] Ikuta Y, et al.: "Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy"Blood. 99(10). 3717-3724 (2002)

    • Related Report
      2002 Annual Research Report

URL: 

Published: 2002-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi